Logo image of INMD

INMODE LTD (INMD) Stock Fundamental Analysis

USA - NASDAQ:INMD - IL0011595993 - Common Stock

15.2911 USD
+0.39 (+2.62%)
Last: 10/1/2025, 3:46:49 PM
Fundamental Rating

7

INMD gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. INMD scores excellent points on both the profitability and health parts. This is a solid base for a good stock. INMD is valued quite cheap, while showing a decent growth score. This is a good combination! With these ratings, INMD could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

In the past year INMD was profitable.
In the past year INMD had a positive cash flow from operations.
Each year in the past 5 years INMD has been profitable.
INMD had a positive operating cash flow in each of the past 5 years.
INMD Yearly Net Income VS EBIT VS OCF VS FCFINMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

1.2 Ratios

INMD has a better Return On Assets (25.23%) than 98.43% of its industry peers.
Looking at the Return On Equity, with a value of 28.44%, INMD belongs to the top of the industry, outperforming 97.91% of the companies in the same industry.
INMD has a Return On Invested Capital of 16.27%. This is amongst the best in the industry. INMD outperforms 95.81% of its industry peers.
INMD had an Average Return On Invested Capital over the past 3 years of 22.89%. This is significantly above the industry average of 8.97%.
The 3 year average ROIC (22.89%) for INMD is well above the current ROIC(16.27%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 25.23%
ROE 28.44%
ROIC 16.27%
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
INMD Yearly ROA, ROE, ROICINMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1.3 Margins

The Profit Margin of INMD (44.50%) is better than 97.91% of its industry peers.
INMD's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 28.54%, INMD belongs to the top of the industry, outperforming 95.29% of the companies in the same industry.
In the last couple of years the Operating Margin of INMD has declined.
The Gross Margin of INMD (79.98%) is better than 92.67% of its industry peers.
INMD's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 28.54%
PM (TTM) 44.5%
GM 79.98%
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
INMD Yearly Profit, Operating, Gross MarginsINMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so INMD is creating value.
Compared to 1 year ago, INMD has less shares outstanding
Compared to 5 years ago, INMD has more shares outstanding
INMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INMD Yearly Shares OutstandingINMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
INMD Yearly Total Debt VS Total AssetsINMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

There is no outstanding debt for INMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.85
WACC8.81%
INMD Yearly LT Debt VS Equity VS FCFINMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

INMD has a Current Ratio of 9.60. This indicates that INMD is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 9.60, INMD belongs to the best of the industry, outperforming 91.62% of the companies in the same industry.
INMD has a Quick Ratio of 8.58. This indicates that INMD is financially healthy and has no problem in meeting its short term obligations.
INMD has a better Quick ratio (8.58) than 91.10% of its industry peers.
Industry RankSector Rank
Current Ratio 9.6
Quick Ratio 8.58
INMD Yearly Current Assets VS Current LiabilitesINMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

INMD shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.04%.
Measured over the past years, INMD shows a very strong growth in Earnings Per Share. The EPS has been growing by 22.97% on average per year.
The Revenue has decreased by -3.61% in the past year.
INMD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.35% yearly.
EPS 1Y (TTM)-4.04%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%38.24%
Revenue 1Y (TTM)-3.61%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%10.59%

3.2 Future

INMD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.56% yearly.
Based on estimates for the next years, INMD will show a small growth in Revenue. The Revenue will grow by 0.74% on average per year.
EPS Next Y-9.82%
EPS Next 2Y-1.69%
EPS Next 3Y1.56%
EPS Next 5YN/A
Revenue Next Year-8.24%
Revenue Next 2Y-1.7%
Revenue Next 3Y0.74%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
INMD Yearly Revenue VS EstimatesINMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
INMD Yearly EPS VS EstimatesINMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2 2.5

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 8.05, the valuation of INMD can be described as reasonable.
Based on the Price/Earnings ratio, INMD is valued cheaply inside the industry as 95.29% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.76. INMD is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 8.89, which indicates a very decent valuation of INMD.
Based on the Price/Forward Earnings ratio, INMD is valued cheaply inside the industry as 95.29% of the companies are valued more expensively.
INMD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.18.
Industry RankSector Rank
PE 8.05
Fwd PE 8.89
INMD Price Earnings VS Forward Price EarningsINMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of INMD indicates a rather cheap valuation: INMD is cheaper than 98.95% of the companies listed in the same industry.
96.86% of the companies in the same industry are more expensive than INMD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 9.29
EV/EBITDA 2.15
INMD Per share dataINMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

The excellent profitability rating of INMD may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.35
EPS Next 2Y-1.69%
EPS Next 3Y1.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INMODE LTD

NASDAQ:INMD (10/1/2025, 3:46:49 PM)

15.2911

+0.39 (+2.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-30 2025-07-30/bmo
Earnings (Next)10-22 2025-10-22/bmo
Inst Owners58.73%
Inst Owner Change-14.05%
Ins Owners10.65%
Ins Owner ChangeN/A
Market Cap966.55M
Analysts72.31
Price Target16.58 (8.43%)
Short Float %6.57%
Short Ratio3.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.54%
Min EPS beat(2)-13.69%
Max EPS beat(2)10.61%
EPS beat(4)2
Avg EPS beat(4)-3.62%
Min EPS beat(4)-20.27%
Max EPS beat(4)10.61%
EPS beat(8)3
Avg EPS beat(8)-6.64%
EPS beat(12)7
Avg EPS beat(12)-0.75%
EPS beat(16)11
Avg EPS beat(16)1.82%
Revenue beat(2)0
Avg Revenue beat(2)-2.62%
Min Revenue beat(2)-2.87%
Max Revenue beat(2)-2.38%
Revenue beat(4)1
Avg Revenue beat(4)-3.67%
Min Revenue beat(4)-9.96%
Max Revenue beat(4)0.53%
Revenue beat(8)1
Avg Revenue beat(8)-7%
Revenue beat(12)5
Avg Revenue beat(12)-3.84%
Revenue beat(16)9
Avg Revenue beat(16)-1.49%
PT rev (1m)0%
PT rev (3m)-4.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.37%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.3%
Valuation
Industry RankSector Rank
PE 8.05
Fwd PE 8.89
P/S 2.41
P/FCF 9.29
P/OCF 9.24
P/B 1.54
P/tB 1.54
EV/EBITDA 2.15
EPS(TTM)1.9
EY12.43%
EPS(NY)1.72
Fwd EY11.25%
FCF(TTM)1.65
FCFY10.76%
OCF(TTM)1.65
OCFY10.82%
SpS6.35
BVpS9.94
TBVpS9.94
PEG (NY)N/A
PEG (5Y)0.35
Profitability
Industry RankSector Rank
ROA 25.23%
ROE 28.44%
ROCE 17.86%
ROIC 16.27%
ROICexc 79.63%
ROICexgc 79.63%
OM 28.54%
PM (TTM) 44.5%
GM 79.98%
FCFM 25.9%
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
ROICexc(3y)532.49%
ROICexc(5y)5023.19%
ROICexgc(3y)532.49%
ROICexgc(5y)5023.19%
ROCE(3y)25.13%
ROCE(5y)28.51%
ROICexcg growth 3Y-60.68%
ROICexcg growth 5YN/A
ROICexc growth 3Y-60.68%
ROICexc growth 5YN/A
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
F-Score7
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 81.89%
Cap/Sales 0.15%
Interest Coverage 250
Cash Conversion 90.67%
Profit Quality 58.19%
Current Ratio 9.6
Quick Ratio 8.58
Altman-Z N/A
F-Score7
WACC8.81%
ROIC/WACC1.85
Cap/Depr(3y)144.54%
Cap/Depr(5y)147.73%
Cap/Sales(3y)0.22%
Cap/Sales(5y)0.23%
Profit Quality(3y)91.09%
Profit Quality(5y)96.73%
High Growth Momentum
Growth
EPS 1Y (TTM)-4.04%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%38.24%
EPS Next Y-9.82%
EPS Next 2Y-1.69%
EPS Next 3Y1.56%
EPS Next 5YN/A
Revenue 1Y (TTM)-3.61%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%10.59%
Revenue Next Year-8.24%
Revenue Next 2Y-1.7%
Revenue Next 3Y0.74%
Revenue Next 5YN/A
EBIT growth 1Y-14.49%
EBIT growth 3Y-12.42%
EBIT growth 5Y13.55%
EBIT Next Year-39.83%
EBIT Next 3Y-11.3%
EBIT Next 5YN/A
FCF growth 1Y-40.81%
FCF growth 3Y-8.8%
FCF growth 5Y16.5%
OCF growth 1Y-40.87%
OCF growth 3Y-8.8%
OCF growth 5Y16.36%